Doxycycline hydrogels as a potential therapy for Ocular vesicant injury

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 5, 2010, Pages 407-419

  Gordon, Marion K ^a   DeSantis, Andrea ^a   Deshmukh, Manjeet ^a   Lacey, Carl Jeffrey ^b   Hahn, Rita A ^a   Beloni, John ^a   Anumolu, Sivanaga S ^c   Schlager, John J ^d   Gallo, Michael A ^e   Gerecke, Donald R ^a   Heindel, Ned D ^b   Svoboda, Kathy K H ^f   Babin, Michael C ^g   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

^b LEHIGH UNIVERSITY   (United States)

^c Sandoz Pharma Ltd   (Switzerland)

^d AIR FORCE RESEARCH LABORATORY   (United States)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f BAYLOR COLLEGE OF DENTISTRY   (United States)

^g BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 TERT BUTYLSANCYCLINE; AMINOTHIOL; CHLORMETHINE; DEDIMETHYLAMINO TETRACYCLINE; DOXYCYCLINE; ETHYL 2 CHLOROETHYL SULFIDE; GELATINASE B; MUSTARD GAS; SANCYCLINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CORNEA; CORNEA EDEMA; CORNEA INJURY; CORNEA THICKNESS; DRUG EFFICACY; DRUG FORMULATION; EYE INJURY; HYDROGEL; IMMUNOFLUORESCENCE; INJURY SEVERITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; RABBIT; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTI-BACTERIAL AGENTS; BASEMENT MEMBRANE; CORNEAL DISEASES; CORNEAL EDEMA; CORNEAL NEOVASCULARIZATION; DOXYCYCLINE; EPITHELIUM, CORNEAL; EYE; EYE INJURIES; HYDROGELS; IRRITANTS; MALE; MECHLORETHAMINE; MUSTARD GAS; NITROGEN MUSTARD COMPOUNDS; RABBITS; TETRACYCLINES;

EID: 77957941542     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0099     Document Type: Article

References (43)

1. Smith, W.J., and Dunn, M.A. Medical defense against blistering chemical warfare agents. Arch. Dermatol. 127:1207-1213, 1991.
2. Papirmeister, B., Feister, A., Robinson, S., et al. Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications. Boca Raton, FL: CRC Press; 1991.
3. Wattana, M., and Bey, T. Mustard gas or sulfur mustard: an old chemical agent as a new terrorist threat. Prehosp. Disaster Med. 24:19-29; discussion 30-31, 2009.
4. Balali-Mood, M., and Hefazi, M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam. Clin. Pharmacol. 19:297-315, 2005.
5. Balali-Mood, M., and Hefazi, M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin. Pharmacol. Toxicol. 99:273-282, 2006.
6. Etezad-Razavi, M., Mahmoudi, M., Hefazi, M., and Balali- Mood, M. Delayed ocular complications of mustard gas poisoning and the relationship with respiratory and cutaneous complications. Clin. Exp. Ophthalmol. 34:342-346, 2006.
7. Ghasemi, H., Ghazanfari, T., Babaei, M., et al. Long-term ocular complications of sulfur mustard in the civilian victims of Sardasht, Iran. Cutan. Ocul. Toxicol. 27:317-326, 2008.
8. Javadi, M.A., and Baradaran-Rafii, A. Living-related conjunctival- limbal allograft for chronic or delayed-onset mustard gas keratopathy. Cornea 28:51-57, 2009.
9. Javadi, M.A., Yazdani, S., Kanavi, M.R., et al. Long-term outcomes of penetrating keratoplasty in chronic and delayed mustard gas keratitis. Cornea 26:1074-1078, 2007.
10. Javadi, M.A., Yazdani, S., Sajjadi, H., et al. Chronic and delayed-onset mustard gas keratitis: report of 48 patients and review of literature. Ophthalmology 112:617-625, 2005. (Pubitemid 41108862)
11. Namazi, S., Niknahad, H., and Razmkhah, H. Long-term complications of sulphur mustard poisoning in intoxicated Iranian veterans. J. Med. Toxicol. 5:191-195, 2009.
12. Shohrati, M., Peyman, M., Peyman, A., Davoudi, M., and Ghanei, M. Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan. Ocul. Toxicol. 26:73-81, 2007.
13. Foreman, D.M., Pancholi, S., Jarvis-Evans, J.,McLeod, D., and Boulton, M.E. A simple organ culture model for assessing the effects of growth factors on corneal re-epithelialization. Exp. Eye Res. 62:555-564, 1996.
14. Carrington, L.M., Albon, J., Anderson, I., Kamma, C., and Boulton, M. Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors. Invest. Ophthalmol. Vis Sci. 47:1886-1894, 2006.
15. Kadar, T., Dachir, S., Cohen, L., et al. Ocular injuries following sulfur mustard exposure-pathological mechanism and potential therapy. Toxicology 263:59-69, 2009.
16. Anumolu, S.S.N., DeSantis, A.S., Menjoge, A.R., et al. Doxycycline loaded poly(ethylene glycol) hydrogels for healing vesicant-induced ocular wounds. Biomaterials 31:964-974, 2010.
17. Anumolu, S.S.N., Singh, Y., Gao, D., Stein, S., Sinko, P.J. Design and evaluation of novel fast forming pilocarpineloaded ocular hydrogels for sustained pharmacological response. J Control Release 137:152-159, 2009.
18. Bernardi, L., Colonna, V., De Castiglione, R., and Masi, P. Tetracycline Derivatives, Belgian Patent No. 804,913, issued March 18, 1974.
19. 2005/000279, filed February 25, 2005.
20. Guignabert, C., Taysse, L., Calvet, J.H., et al. Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs. Am. J. Physiol. Lung Cell Mol. Physiol. 289:L67-L74, 2005.
21. Petrinec, D., Liao, S., Holmes, D.R., et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aorticelastin associated with suppressed production of 92kD gelatinase. J. Vasc. Surg. 23:336-346, 1996.
22. Ghassemi-Broumand, M., Agin, K., and Kangari, H. The delayed ocular and pulmonary complications of mustard gas. J. Toxicol. Cutan. Ocul. Toxicol. 23:293-302, 2004.
23. Papirmeister, B., Gross, C.L., Meier, H.L., Petrali, J.P., and Johnson, J.B. Molecular basis for mustard-induced vesication. Fundam. Appl. Toxicol. 5:S134-S149, 1985.
24. Kadar, T., Turetz, J., Fishbine, E., et al. Characterization of acute and delayed ocular lesions induced by sulfur mustard in rabbits. Curr. Eye Res. 22:42-53, 2001.
25. Safarinejad, M.R., Moosavi, S.A., and Montazeri, B. Ocular injuries caused by mustard gas: diagnosis, treatment, and medical defense. Mil. Med. 166:67-70, 2001.
26. Kabosova, A., Kramerov, A.A., Aoki, A.M., et al. Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp. Eye Res. 77:211-217, 2003.
27. Piehl, M., Gilotti, A., Donovan, A., DeGeorge, G., and Cerven, D. Novel cultured porcine corneal irritancy assay with reversibility endpoint. Toxicol. In Vitro 24:231-239, 2010.
28. Richard, N.R., Anderson, J.A., Weiss, J.L., and Binder, P.S. Air/liquid corneal organ culture: a light microscopic study. Curr. Eye Res. 10:739-749, 1991.
29. Saghizadeh, M., Kramerov, A.A., Yu, F.S., Castro, M.G., and Ljubimov, A.V. Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. Invest. Ophthalmol. Vis. Sci. 51:1970-1980, 2010.
30. Zhao, B., Cooper, L.J., Brahma, A., et al. Development of a three-dimensional organ culture model for corneal wound healing and corneal transplantation. Invest. Ophthalmol. Vis. Sci. 47:2840-2846, 2006.
31. Derby, G.S. Ocular manifestations following exposure to various types of poisonous gases. Trans. Am. Ophthalmol. Soc. 17:90-105, 1919.
32. Derby, G.S. Medical-social service and follow-up work in the eye hospital. Trans. Am. Ophthalmol. Soc. 18:41-48, 1920.
33. Ireland, M. Medical Aspects of Gas Warfare, the Medical Department of the United States Army in the World War. Washington, DC: U.S. Government Printing Office; 1926; pp. 1-769.
34. Garrana, R.M., Zieske, J.D., Assouline, M., and Gipson, I.K. Matrix metalloproteinases in epithelia from human recurrent corneal erosion. Invest.Ophthalmol. Vis. Sci. 40:1266-1270, 1999.
35. Curci, J.A., Petrinec, D., Liao, S., Golub, L.M., and Thompson, R.W. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J. Vasc. Surg. 28:1082-1093, 1998.
36. Golub, L.M., Lee, H.M., Lehrer, G., et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J. Periodontal Res. 18:516-526, 1983.
37. Golub, L.M., McNamara, T.F., D'Angelo, G., Greenwald, R.A., and Ramamurthy, N.S. A non-antibacterial chemicallymodified tetracycline inhibits mammalian collagenase activity. J. Dent. Res. 66:1310-1314, 1987.
38. Dursun, D., Kim, M.C., Solomon, A., and Pflugfelder, S.C. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am. J. Ophthalmol. 132:8-13, 2001.
39. Liu, Y., Ryan, M.E., Lee, H.M., et al. A chemically modified tetracycline (CMT-3) is a new antifungal agent. Antimicrob. Agents Chemother. 46:1447-1454, 2002.
40. Amir, A., Turetz, J., Chapman, S., et al. Beneficial effects of topical anti-inflammatory drugs against sulfur mustardinduced ocular lesions in rabbits. J. Appl. Toxicol. 20 Suppl 1: S109-S114, 2000.
41. Deshmukh, M., Singh, Y., Gunaseelan, S., Gao, D., Stein, S., and Sinko, P.J. Biodegradable poly(ethylene glycol) hydrogels based on a self-elimination degradation mechanism. Biomaterials. 31:6675-6684, 2010.
42. Lalloo, A., Chao, P., Hu, P., Stein, S., Sinko, P.J. Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. J Control Release 112:333-342, 2006.
43. Qiu, B., Stefanos, S., Ma, J., Lalloo, A., Perry, B.A., Leibowitz, M.J., Sinko, P.J. and Stein, S. A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)- based copolymer: a new biomaterial for protein drug delivery. Biomaterials. 24:11-18, 2003.